GLP1Agonists and SGLT2 Inhibitors Table
Date Added:
March 10, 2022
Publication Date:
February 6, 2022
Type:
Meta-analyses, Reviews, and Guidelines
Format:
Poster
Abstract
Based upon the following two meta-analyses:
1. Alexander JT, et al. The longer-term benefits and harms of glucagon-like peptide-1 receptor agonists: A Systematic review and meta-analysis. JGIM, 2021; 7(2): 415-43.
2. Alexander JT, et al. Longer-term benefits and risks of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: A systematic review and meta-analysis. JGIM, 2021; 37(2): 439-44, plus Supplementary materials at https://doi.org/10.1007/s11606-021-07227-0.
Selection criteria for the RCTs was that the study period was at least 52 weeks in duration. I assume the average duration of the studies was at least 2 years. So, an absolute risk reduction of mortality of 0.5% would be per 2+ years.
Text Availability
Free full text
RPR Commentary
This table shows the relative risk reduction (RRR) and absolute risk reduction (ARR) as percentages for GLP1 agonists and SGLT2 Inhibitors, based upon RCTs of at least one year duration. In most cases, the participants were at high risk for adverse CV events, but the ARRs were still fairly small, with insufficient information about how these drugs perform vs. other, less expensive antihyperglycemic agents. James W. Mold, MD, MPH